Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Profit of driving school Svetofor according to RAS in 2022 increased by 25 times

4/5/23 SVET

Fesco set up a subsidiary in Belarus to develop import and export shipments

4/5/23 FESH

FAS is developing a plan to split RusHydro into generation and networks

4/5/23 HYDR

Moscow Exchange has bought a controlling stake in a developer of solutions for compliance automation

4/5/23 MOEX

VTB will not pay dividends for 2023, despite returning to profits

4/5/23 VTBR

Sistema-Biotech releases technology to produce cancer drugs

4/5/23 AFKS

VTB reports record loss in 2022

4/5/23 VTBR

SPB Exchange summarized the results of trading in March

4/5/23 SPBE

Trading volume on Moscow Exchange in March decreased by 31.7%

4/4/23 MOEX

Gazprombank wants to recover from Mechel ₽11.9 billion

4/4/23 MTLR